N-[2-(苄氧基)乙基]-N-乙胺 | 104678-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[2-(苄氧基)乙基]-N-乙胺
• 英文名称: N-[2-(benzyloxy)ethyl]-N-ethylamine
• 英文别名: N-ethyl-2-phenylmethoxyethanamine
• CAS: 104678-17-3
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: WHADWYFKFZANJL-UHFFFAOYSA-N

物化性质

• 沸点：
  248.3±15.0 °C(Predicted)
• 密度：
  0.958±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(苄氧基)乙基]-N-乙胺 在 sodium hydroxide 、 TEA 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 (2S)-2-[[ethyl(2-phenylmethoxyethyl)carbamoyl]amino]-3-phenylpropanoic acid
  参考文献：
  名称：

  A novel series of urea-based peptidomimetic calpain inhibitors

  摘要：

  A series of peptide aldehyde derivatives in which the P-2 chiral carbon has been replaced with nitrogen were synthesized as urea-based peptidomimetic inhibitors of mu-calpain. The compounds mirrored the general SAR of peptidyl aldehyde calpain inhibitors but displayed greater selectivity for mu-calpain over cathepsin B. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.068
• 作为产物：
  描述：

  苄氧基乙醛 、 乙胺 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 N-[2-(苄氧基)乙基]-N-乙胺
  参考文献：
  名称：

  A novel series of urea-based peptidomimetic calpain inhibitors

  摘要：

  A series of peptide aldehyde derivatives in which the P-2 chiral carbon has been replaced with nitrogen were synthesized as urea-based peptidomimetic inhibitors of mu-calpain. The compounds mirrored the general SAR of peptidyl aldehyde calpain inhibitors but displayed greater selectivity for mu-calpain over cathepsin B. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.068

文献信息

• CuCl₂-catalyzed highly stereoselective and chemoselective reduction of alkynyl amides into α,β-unsaturated amides using silanes as hydrogen donors
  作者：Lingfei Duan、Kai Jiang、Hua Zhu、Biaolin Yin

  DOI：10.1039/d0ob02037k

  日期：——

  CuH-catalyzed Z-selective partial reduction of alkynyl amides to afford α,β-unsaturated amides using silane as the hydrogen donor is developed. This reaction is carried out under mild conditions and able to accommodate a broad scope of alkynyl amides including those bearing a terminal carbon–carbon double bond or triple bond, affording alkenyl amides with high stereoselectivity and excellent yields.

  利用硅烷作为氢供体，开发了CuH催化的炔基酰胺的Z选择性部分还原，制得α，β-不饱和酰胺。该反应在温和的条件下进行，能够容纳广泛的炔基酰胺，包括带有末端碳-碳双键或三键的炔基酰胺，从而提供具有高立体选择性和优异收率的烯基酰胺。
• Pyrazolopyrimidinone derivatives having PDE7 inhibiting action
  申请人：Inoue Hidekazu

  公开号：US20050148604A1

  公开（公告）日：2005-07-07

  Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): and the following general formula (IA′) or (IB′): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds have the action of selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, they are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

  本发明提供了以下通式(IA)或(IB)所表达的吡唑并嘧啶酮衍生物，以及以下通式(IA′)或(IB′)所表达的吡唑并嘧啶酮衍生物：其中所述符号如本说明书所披露的那样，作为所需的化合物提供。这些化合物具有选择性地抑制PDE7的作用，从而增加细胞内cAMP水平并抑制T细胞的活化。因此，它们对于预防和治疗各种过敏性疾病和炎症或免疫性疾病是有用的。
• 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action
  申请人：Ausbio Pharma Co., Ltd.

  公开号：US07268128B2

  公开（公告）日：2007-09-11

  Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, these compounds are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

  以下一般式（IA）或（IB）所表示的吡唑并嘧啶酮衍生物： 其中符号如说明书所述，作为所需的化合物提供。这些化合物选择性地抑制PDE7，从而增加细胞内cAMP水平并抑制T细胞的活化。因此，这些化合物对于预防和治疗各种过敏性疾病和炎症或免疫性疾病非常有用。
• PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY
  申请人：Daiichi Suntory Pharma Co., Ltd.

  公开号：EP1454897A1

  公开（公告）日：2004-09-08

  Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): and the following general formula (IA') or (IB'): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds have the action of selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, they are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

  由以下通式（IA）或（IB）表示的吡唑嘧啶酮衍生物： 和以下通式（IA'）或（IB'）表示的吡唑嘧啶酮衍生物： 其中的符号如说明书中所披露的，作为所需的化合物提供。 这些化合物具有选择性抑制 PDE7 的作用，从而提高细胞内 cAMP 水平并抑制 T 细胞的活化。因此，它们可用于预防和治疗各种过敏性疾病和炎症性或免疫性疾病。
• PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY
  申请人：Asubio Pharma Co., Ltd.

  公开号：EP1454897B1

  公开（公告）日：2007-10-10